Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Warrants (Tables)

Warrants (Tables)

6 Months Ended

Jun. 30, 2019

The following is a summary of warrant activity for the six months ended June 30, 2019 and 2018:


		Weighted Average		Weighted Average
	Number of	Exercise		Remaining
	Warrants	Price		Term in Years
Outstanding at December 31, 2018	40,844,086	$	1.00	4.05
Exercised	(100,000)		0.32	3.80
Outstanding at June 30, 2019	40,744,086		1.00	3.55

Outstanding at December 31, 2017	9,455,961		3.26	4.23
Issued	35,156,250		0.32	4.80
Exercised	(2,356,875)		0.32	4.80
Outstanding at June 30, 2018	42,255,336	$	0.98	4.56

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details